Tiragolumab - Genentech
Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284Latest Information Update: 01 Jul 2025
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
Most Recent Events
- 26 Jun 2025 M. D. Anderson Cancer Center plans the phase II STRIVE trial for Lung cancer, Squamous cell cancer, and Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV), in December 2025 (NCT07038915)
- 25 Apr 2025 Efficacy and adverse events data from a phase III SKYSCRAPER-01 trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Mar 2025 Roche completes a phase II trial in Non-small cell lung cancer (Adjuvant therapy, Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA, Switzerland, Australia, Italy, Netherlands, Poland, South Korea, Spain (IV) (NCT04832854)